On October 2, 3SBIO fell 5.61% in regular trading, trading at 15.58 HKD/share, with turnover of approximately 48.25 million HKD.

Within the Biotechnology sector where 3SBIO belongs, the overall sector was under broad selling pressure. Among individual stocks, BEONE MEDICINES down 6.65%, INNOVENT BIO down 4.95%, AKESO down 4.14%, SKB BIO down 5.67%, REMEGEN down 7.91%.

3SBIO is an investment holding company principally engaged in the development, manufacturing, marketing, and sale of biopharmaceutical products. Its key products include TPIAO, EPIAO, YISAIPU, and other biologics, as well as MANDI and other small-molecule drugs. The company also operates a CDMO business. In its most recent interim results disclosed on August 20, the company reported revenue of RMB 4.526 billion, up 3.9% year-over-year, while net profit attributable to shareholders declined 15.6% to RMB 1.147 billion. The company has been conducting frequent share buybacks throughout September, cumulatively repurchasing over 10 million shares.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)